A Phase 2 Study of AG-946 in People with Anemia Due to Myelodysplastic Syndromes


Full Title

A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized, Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes


In this study, researchers are assessing the safety and effectiveness of the drug AG-946 for people with anemia (a low number of red blood cells) due to lower-risk myelodysplastic syndromes (MDS). In people with lower-risk MDS, the disease is more likely to worsen slowly and may cause mild to moderate anemia. AG-946 can help produce more energy within each red blood cell in the body and may improve anemia. It is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have anemia due to lower-risk MDS.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Tamanna Haque at 646-608-4166.




Phase II (phase 2)

Disease Status

Newly Diagnosed



ClinicalTrials.gov ID